<DOC>
	<DOC>NCT02631096</DOC>
	<brief_summary>The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467</brief_summary>
	<brief_title>Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy</brief_title>
	<detailed_description>Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative subjects and one cohort of HBeAg-positive subjects. All subjects will be non-cirrhotic, with chronic hepatitis B virus (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with entecavir or tenofovir for at least 12 months.</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>Key Documented chronic HBV infection for ≥12 months prior to Screening Visit. Quantitative HBsAg ≥1000 IU/mL at the Screening Visit. Subjects currently receiving entecavir or tenofovir for ≥12 months and HBV DNA undetectable. Key Known coinfection with HIV, hepatitis C virus, or hepatitis D virus. Receiving or planning to receive systemic immunosuppressive medications during the study or ≤2 months prior to the first dose of study treatment. Receiving or planning to receive interferon during the study or ≤12 months prior to the first dose of study treatment. Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia. Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the Screening Visit. Any known preexisting medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>